CN1242801C - Medicinal composition for treating coronary heart disease and angine pectoris - Google Patents
Medicinal composition for treating coronary heart disease and angine pectoris Download PDFInfo
- Publication number
- CN1242801C CN1242801C CN 02159209 CN02159209A CN1242801C CN 1242801 C CN1242801 C CN 1242801C CN 02159209 CN02159209 CN 02159209 CN 02159209 A CN02159209 A CN 02159209A CN 1242801 C CN1242801 C CN 1242801C
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- angina pectoris
- paeoniae rubra
- leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses the formulation and a preparation method of a medicine composition for treating coronary disease and angina pectoris. The medicine composition comprises components of total saponins of stems and leaves of ginseng, red peony root and curcuma root, wherein the red peony root is extracted in a water boiling and alcohol sinking method. The medicine composition can be made into the preparation of capsule preparation or granular preparation or oral liquid preparation or other proper preparation. The present invention is also suitable for treating coronary disease in forms of insufficient cardiac blood supply, myocardial infarction, arrhythmia, cardiac functional insufficiency, etc.
Description
(1) technical field
The present invention relates to be used to prevent and treat treating coronary heart disease and angina pectoris, particularly the pharmaceutical preparation of preparing with Chinese crude drug.
(2) background technology
Angina pectoris is the healthy commonly encountered diseases of serious harm middle-aged and elderly people, frequently-occurring disease.Modern medicine focuses on the allevating angina pectoris acute symptom mostly to the medical treatment medicine of primary disease, is difficult to reach persistent stable curative effect.And these medicines are in usual amounts, or when removing angina pectoris symptom rapidly and strengthen consumption, bigger side effect usually occurs.Chinese medicine the Chinese patent medicine of certain curative effect occurred much the treatment angina pectoris being had, as Radix Salviae Miltiorrhizae Tabellae, FUFANG DANSHEN PIAN, Radix Salviae Miltiorrhizae drop pill, DIAOXINXUE KANG preparation, TONGXINLUO JIAONANG etc. in characteristic and advantage that oneself is arranged aspect the treatment angina pectoris.But these shortcomings that Chinese patent medicine ubiquity curative effect is low, onset is slow often need to use simultaneously with multiple Western medicine.All contain the Borneolum Syntheticum quasi-mineral for another preparations such as FUFANG DANSHEN PIAN and TONGXINLUO JIAONANG, irritate gastrointestinal easily, influence untoward reaction such as optic nerve.Also there is the anaphylactoid problem of initiation in TONGXINLUO JIAONANG.
The Chinese patent medicine ginseng Chinese herbaceous peony sheet that No. 93103012 Chinese invention patent methods that provide according to the inventor are produced, part has overcome the shortcoming of above-mentioned Chinese patent medicine, and clinical practice more than ten years are obtained certain curative effect.This medicine biggest advantage is without any side effect, and patient takes comparison safety for a long time.But the curative effect of ginseng Chinese herbaceous peony sheet is still lower, and function of promoting blood circulation to disperse blood clots can not be satisfactory.Therefore, the advantage of performance Chinese medicine aspect treatment coronary heart disease, excavation better efficacy, side effect Chinese patent medicine still less are the needs of clinical treatment.
(3) summary of the invention
The object of the present invention is to provide a kind ofly, the pharmaceutical preparation of better curative effect is arranged angina pectoris, myocardial infarction, cardiac insufficiency treating both the principal and secondary aspects of a disease.
Pharmaceutical composition of the present invention is prepared by following components in weight percentage:
Stem and leaf of Radix Ginseng total saponins 0.5～2.0% Radix Paeoniae Rubra 86～90% Radix Curcumaes 9～12.5%
The optimum weight percentage ratio of above-mentioned each component is,
Stem and leaf of Radix Ginseng total saponins 0.7% Radix Paeoniae Rubra 88.7% Radix Curcumae 10.6%
Chinese crude drug Radix Curcumae in the said components has " RADIX CURCUMAE ", " yellow silk Radix Curcumae ", " osmanthus Radix Curcumae ", " green filament Radix Curcumae " not, preferably yellow silk Radix Curcumae.
The basic skills that above each component raw material medicine is made medicament is that the process of the Radix Paeoniae Rubra in the component being pressed " decocting in water precipitate with ethanol " gets extract; Radix Paeoniae Rubra extract is mixed with turmeric powder, stem and leaf of Radix Ginseng saponin's powder, be equipped with the pharmacy acceptable carrier, manufacture dosage form alleged on the pharmaceutics, for example capsule, tablet, granular pattern electuary, oral liquid or other dosage forms that is suitable for.
Drug regimen composition formula of the present invention has increased the drug for invigorating blood circulation and eliminating stasis Radix Curcumae than No. 93103012 Chinese invention patents, has also adjusted the usage ratio of each medicine.Radix Curcumae is the traditional drug for invigorating blood circulation and eliminating stasis of the traditional Chinese medical science, also is present a kind of blood circulation promoting and blood stasis dispelling Chinese medicine commonly used and important.Be the yellow silk of zingiberaceous plant Radix Curcumae, the classic of TCM thinks, Radix Curcumae is that circulation of qi promotingization is strongly fragrant, the good medicine of the removing heat from blood that clears away heart-fire, drastically removing blood stasis and resolving static blood, treatment " trusted subordinate's obstinate disease ".Great mass of data shows, Radix Curcumae is except that having activating blood circulation and supplementing qi, disperse blood stasis and dredge collateral, anti-cardiac-cerebral ischemia, antiplatelet aggregation, anti-hyperlipidemia effect, also have the effect of the tunica intima that antiallergic, free radical resisting, detoxifcation, blood fat reducing, reparation damage because of arteriosclerosis, nerve, endocrine, immune system are all had stronger physiologically active.These pharmacological actions of Radix Curcumae are significant to the holistic health quality that improves cardiovascular patient.Pharmacology test proves, Radix Curcumae can expand animal arteria coronaria, coronary blood flow increasing, microcirculation improvement, blood fat reducing, the vascular endothelial cell of arteriosclerosis infringement is had repair, experimental arrhythmia is had notable therapeutic effect.
Press tcm theory, Radix Paeoniae Rubra is monarch drug in drug regimen composition formula of the present invention.Effects such as Radix Paeoniae Rubra has blood circulation promoting and blood stasis dispelling, relieving spasm to stop pain, coronary artery dilating, coronary blood flow increasing, reduction myocardial oxygen consumption, resists myocardial ischemia, antiplatelet aggregation, antithrombotic formation.Pharmacology of Chinese materia medica studies show that, the Radix Paeoniae Rubra hydrotrope can prolong the anoxybiotic time-to-live of animal cardiac muscle due to the isoproterenol, and antagonism causes that by pituitrin the electrocardiogram of animal changes, and it is right to increase mouse cardiac muscle
86The intake of Rb, thereby the nutritional blood flow amount of increase mouse cardiac muscle.Clinical trial certificate Radix Paeoniae Rubra can prevent and treat diseases such as angina pectoris, myocardial infarction and cerebral ischemia.It is because of its property of medicine is gentle that we solely get Radix Paeoniae Rubra, invigorates blood circulation and removing blood stasis not, and anticoagulation and not causing bleeding has tall and erect the effect to improving cardiovascular function.Modern pharmacology studies have shown that the main effective ingredient of Radix Paeoniae Rubra is a peoniflorin.
Pharmaceutical preparation of the present invention is earlier Radix Paeoniae Rubra to be decocted with water, and the method for reuse ethanol precipitation is removed water extract impurity, reaches the purpose of purification.Concentration of alcohol selects 60%～90% for use, with 70% the best.
Another component stem and leaf of Radix Ginseng total saponins of the present invention, evidence, it has and Radix Ginseng and the essentially identical characteristics of Radix Ginseng total saponins the pharmacological action of cardiovascular system: arteria coronaria, coronary blood flow increasing, treatment cardiac insufficiency and the cardiogenic shock etc. of expansion animal.Outside, stem and leaf of Radix Ginseng total saponins also has protective effect to the cardiac muscle that anoxia lacks sugar, to the DNA of neonatal rat myocardial cell is synthetic facilitation is arranged.By theory of Chinese medical science, stem and leaf of Radix Ginseng total saponins mainly works the effect of regulating the flow of vital energy in we, and has circulation of qi promoting and the characteristics of dispelling the stagnated QI not.
More than three medicines combinations, blood circulation promoting and blood stasis dispelling, QI invigorating pain relieving, strengthening the body resistance, and anticoagulation, antiplatelet aggregation, anti-hyperlipidemia, microcirculation improvement effect are arranged.
Pharmacology, pharmacodynamic experiment that medicine of the present invention is carried out show, this medicine can obviously increase the coronary flow of dog and myocardial flow, cardiac index, heartbeat index, cardiac output; Reduce myocardial oxygen consumption and myocardium oxygen uptake rate; Reduce coronary resistance, total peripheral resistance; Obviously reduce degree of myocardial ischemia, myocardial ischemia scope and myocardial infarct size; Can reduce simultaneously the content of Serum LDH (lactic acid dehydrogenase), AST (aspartate aminotransferase) and CPK (serum paraoxonase creatine phosphate kinase).Can alleviate the damage that causes Acute Myocardial Ischemia in Rats because of the injection isoproterenol, the rat plasma MDA that isoproterenol is caused raises inhibitory action is arranged simultaneously; Can significant prolongation mice cause time-to-live under myocardial ischemia, the anoxia condition at normobaric hypoxia and isoproterenol; Suppress the rat thrombus in vivo and form, reduce the blood viscosity of blood stasis model rat, improve hemorheological property.The experiment and show that this medicine does not have toxicity.The present invention of clinical practice proof has better curative effect to the treatment cardiovascular diseases.Not only the treatment angina pectoris there is good efficacy, also can be used for treating the coronary heart disease of forms such as heart blood supply insufficiency, myocardial infarction, arrhythmia, cardiac insufficiency.
The quality control of pharmaceutical preparation of the present invention can adopt TLC (thin layer chromatography) method and HPLC (high performance liquid chromatography) method to measure paeoniflorin content; Radix Curcumae medical material, the pure product of stem and leaf of Radix Ginseng saponin are carried out TLC to be differentiated.
(4) specific embodiment
The invention will be further described by the following examples.
Embodiment 1 produces capsule
Take by weighing Radix Paeoniae Rubra 1750 grams, stem and leaf of Radix Ginseng total saponins 13 grams, Radix Curcumae 210 grams.
Radix Paeoniae Rubra soaked after 2 hours decoct each 1 hour 2 times.Merging filtrate, being concentrated into relative density is 1.05～1.10 (50 ℃ of mensuration), removes water extract impurity, decompression recycling ethanol with the method for 70% ethanol precipitation.Vacuum drying becomes dry extract, pulverizes, and sieves, and adds stem and leaf of Radix Ginseng total saponins, turmeric powder, mixing, dry (below 60 ℃), encapsulated 1000 promptly.Each oral 4 of general adult, 2 times on the 1st.
Embodiment 2 produces tablet
Take by weighing Radix Paeoniae Rubra 3500 grams, stem and leaf of Radix Ginseng total saponins 60 grams, Radix Curcumae 500 grams.
Radix Paeoniae Rubra soaked after 3 hours decoct each 1 hour 2 times.Merging filtrate, being concentrated into relative density is 1.05～1.10 (50 ℃ of mensuration), removes water extract impurity, decompression recycling ethanol with the method for 70% ethanol precipitation.Vacuum drying becomes dry extract, pulverizes, and sieves, and adds stem and leaf of Radix Ginseng total saponins, turmeric powder mixing, dry (below 60 ℃), 4000 of tablettings.Each oral 4 of general adult, 3～4 times on the 1st.
Embodiment 3 treatment angina pectoris 108 routine observation of curative effect
(1) case selection standard and test method
According to the coronary heart disease diagnosis standard,, select 200 examples to reach outpatient service angina pectoris patient in hospital and be divided into treatment group and matched group at random with reference to " name of ischemic heart desease and the diagnostic criteria " that WHO formulates.Male 68 examples in 108 examples, women 40 examples are organized in treatment; 38～77 years old age, 57,66 years old mean age.Male 55 examples in matched group 92 examples, women 37 examples, 56,44 years old mean age.There is not significant difference between two groups of ages, sex.
The oral pained stator 10mg of matched group, 3 times on the 1st.The oral capsule of making according to embodiment 1 method of treatment group, each 4,2 times on the 1st.Be 30 days two groups of courses of treatment.
(2) observation index and curative effect determinate standard
Two groups of cases are all observed, 1. angina pectoris weekly attack times variation and use the increase and decrease of nitroglycerin amount; 2. Electrocardiographic variation before and after the treatment.
The curative effect of angina pectoris symptom and ECG curative effect are with reference to national therapy of combining Chinese and Western medicine angina pectoris in 1979 and arrhythmia research forum " angina pectoris and ECG curative effect evaluation criteria ".
(3) result
1. to the curative effect of angina pectoris symptom: treatment group total effective rate is 92.59%, and the matched group total effective rate is that 79.35%, two group of curative effect difference has highly significant (P＜0.05), sees Table 1.
The curative effect of table 1 angina pectoris symptom [example (%)]
| Group | Example | Produce effects | Effectively | Invalid | Total effective rate (%) | |||
| Example | ％ | Example | ％ | Example | ％ | |||
| The treatment group | 108 | 46 | 42.59 | 54 | 50.00 | 8 | 7.41 | 92.59 |
| Matched group | 92 | 28 | 30.43 | 45 | 48.92 | 19 | 20.65 | 79.35 |
2. to Electrocardiographic curative effect: the treatment group obviously is better than matched group (P＜0.05), sees Table 2.
Table 2 a liang group electrocardiogram changes relatively
| Group | Example | Produce effects | Effectively | Invalid | Total effective rate (%) | |||
| Example | ％ | Example | ％ | Example | ％ | |||
| The treatment group | 108 | 19 | 17.59 | 41 | 37.96 | 48 | 44.45 | 55.55 |
| Matched group | 92 | 12 | 13.04 | 21 | 22.83 | 59 | 64.13 | 35.87 |
3. to the influence of nitroglycerin consumption: the two groups of patient's nitroglycerin consumptions in treatment back always stop lapse rate and are respectively 79.17% and 70.21%, relatively do not have significant difference between group, see Table 3.
Table 3 a liang group patient nitroglycerin stops lapse rate relatively
| Group | Example | Drug withdrawal | Decrement | No change | Always stop to subtract | ||||
| Example | ％ | Example | ％ | Example | ％ | The example number | ％ | ||
| The treatment group | 48 | 24 | 50.00 | 14 | 29.17 | 10 | 20.83 | 38 | 79.14 |
| Matched group | 47 | 20 | 42.55 | 13 | 27.66 | 14 | 29.79 | 33 | 70.21 |
Clinical observation shows that medicine energy allevating angina pectoris symptom of the present invention reduces seizure frequency, shortens duration of seizure, simultaneously electrocardiogram is improved significantly.
Embodiment 4 treatment angina pectoris 68 routine observation of curative effect
(-) case selection standard and test method
According to diagnostic criteria for coronary heart disease,, select to be in hospital and outpatient service angina pectoris patient with reference to " name of ischemic heart desease and the diagnostic criteria " that WHO formulates.68 examples are organized in treatment, wherein male 48 examples, women 20 examples; 36～69 years old age, 56.22 years old mean age; Average course of disease 4.63.All case gives the oral tablet of making according to embodiment 2 methods, each 4, every day 4 times.Matched group 46 examples, wherein male 32 examples, women 14 examples; 54～70 years old age, 53.78 years old mean age; 3.45 courses of treatment of average course of disease.The oral pentaerythritol tetranitrate sheet of matched group 10mg, 3 times on the 1st.Two groups equal 30 days be 1 course of treatment.
(2) observation index and curative effect determinate standard
Two groups of cases are all observed, the 1. variation that shows effect weekly of angina pectoris; 2. Electrocardiographic variation before and after the treatment.
Angina pectoris symptom and ECG curative effect are with reference to national therapy of combining Chinese and Western medicine angina pectoris in 1979 and arrhythmia research forum " angina pectoris and ECG curative effect evaluation criteria ".
(3) result
1. to the curative effect of angina pectoris symptom: the angina pectoris total effective rate is 94.12% after the Drug therapy of the present invention, and matched group angina pectoris total effective rate is that 86.96%, two group of curative effect has significant difference (P＜0.05), sees Table 1.
The curative effect of table 1 liang group patient angina pectoris symptom relatively
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate % | |||
| Example | ％ | Example | ％ | Example | ％ | |||
| The treatment group | 68 | 14 | 20.59 | 50 | 73.53 | 4 | 5.88 | 94.12* |
| Matched group | 46 | 9 | 19.57 | 31 | 67.39 | 6 | 13.04 | 86.96 |
Annotate: 1. compare with matched group; 2. * P＜0.05
2. to Electrocardiographic curative effect: there was no significant difference between treatment group and the matched group (P＞0.05) sees Table 2.
Table 2 liang group ECG curative effect relatively
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate % | |||
| Example | ％ | Example | ％ | Example | ％ | |||
| The treatment group | 68 | 13 | 19.12 | 21 | 30.88 | 34 | 50.00 | 50.00△ |
| Matched group | 46 | 8 | 17.39 | 14 | 30.43 | 24 | 52.18 | 47.82 |
Annotate: 1. compare with matched group; 2. △ P＞0.05.
3. to the influence of nitroglycerin consumption: see Table 3.
Nitroglycerin stopped lapse rate before and after table 3 a liang group was suffered from treatment
| Group | Example | Drug withdrawal | Decrement | No change | Always stop to subtract | ||||
| Example | ％ | Example | ％ | Example | ％ | The example number | ％ | ||
| The treatment group | 32 | 20 | 62.50 | 8 | 25.00 | 4 | 12.50 | 28 | 87.50 |
| Matched group | 21 | 9 | 42.86 | 7 | 33.33 | 5 | 23.81 | 16 | 76.19 |
Annotate: compare with matched group (1); (2) * P＜0.05.
Can find out from table 3. it is 76.19% for the 87.50%. matched group that treatment group nitroglycerin consumption always stops lapse rate.Two groups in the treatment in nitroglycerin stop lapse rate significant difference (P＜0.05).
Do not find untoward reaction during the test of cure.
Conclusion: through Drug therapy of the present invention after 30 days curative effect to treat angina pectoris better.Treatment back nitroglycerin consumption obviously reduces, and angina pectoris attacks obviously reduces, and does not find untoward reaction.
Claims (7)
1. a treatment treating coronary heart disease and angina pectoris compositions is characterized in that it is the medicament of being made by following materials of weight proportions medicine: stem and leaf of Radix Ginseng total saponins 0.5～2.0%, Radix Paeoniae Rubra 86～90%, Radix Curcumae 9～12.5%.
2. pharmaceutical composition according to claim 1, wherein the weight proportion of each crude drug is: stem and leaf of Radix Ginseng total saponins 0.7%, Radix Paeoniae Rubra 88.7%, Radix Curcumae 10.6%.
3. according to any one described pharmaceutical composition of claim 1～2, wherein said Radix Curcumae is yellow silk Radix Curcumae.
4. according to any one described pharmaceutical composition of claim 1～2, wherein said medicament is capsule, tablet.
5. according to any one described preparation of drug combination method of claim 1～2, it is characterized in that Radix Paeoniae Rubra wherein gets extract by " decocting in water precipitate with ethanol " method, mix with turmeric powder, stem and leaf of Radix Ginseng saponin's powder, be equipped with the pharmacy acceptable carrier, manufacture medicament.
6. preparation of drug combination method according to claim 5, wherein used concentration of alcohol is 60%～90%.
7. preparation of drug combination method according to claim 5, wherein used concentration of alcohol is 70%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159209 CN1242801C (en) | 2002-12-30 | 2002-12-30 | Medicinal composition for treating coronary heart disease and angine pectoris |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159209 CN1242801C (en) | 2002-12-30 | 2002-12-30 | Medicinal composition for treating coronary heart disease and angine pectoris |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511555A CN1511555A (en) | 2004-07-14 |
| CN1242801C true CN1242801C (en) | 2006-02-22 |
Family
ID=34237364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02159209 Expired - Fee Related CN1242801C (en) | 2002-12-30 | 2002-12-30 | Medicinal composition for treating coronary heart disease and angine pectoris |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1242801C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316993C (en) * | 2005-09-28 | 2007-05-23 | 马耀茹 | Medicine for treating cerebral infarction, coronary heart disease and angina pectoris |
-
2002
- 2002-12-30 CN CN 02159209 patent/CN1242801C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1511555A (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN101708237B (en) | Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof | |
| CN100339111C (en) | Medicine for treating coronary heart disease and its prepn | |
| CN1058614C (en) | Galenic composition | |
| CN101129464A (en) | Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same | |
| CN1242801C (en) | Medicinal composition for treating coronary heart disease and angine pectoris | |
| CN1253198C (en) | Medicinal composition for treating coronary heart disease and angina pectoris | |
| CN101279034A (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN1593489A (en) | Traditional Chinese Medicinal formulation for treating coronary heart disease and preparation method thereof | |
| CN1310662C (en) | Chinese medicine for coronary heart disease | |
| CN1254252C (en) | Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN1228332A (en) | Drug for curing migraine and its preparing method | |
| CN1202847C (en) | Diabetes treating medicine | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN101099836B (en) | Traditional Chinese medicine composition for treating ischemic apoplexy and preparation process thereof | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1269493C (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN108704105A (en) | A kind of Chinese medicine composition for treating Acute Cerebral Infarction | |
| CN1293971A (en) | Medicine for treating apoplexy and its preparing process | |
| CN1316992C (en) | Medicine for treating heart brain embulus disease and its preparation method | |
| CN112294901B (en) | Traditional Chinese medicine composition for treating supraventricular arrhythmia and preparation method and application thereof | |
| CN1287836C (en) | Chinese medicinal powder for treating diabetes and its production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060222 Termination date: 20151230 |
|
| EXPY | Termination of patent right or utility model |